Skip to main content
. 2022 May 26;40(31):3633–3641. doi: 10.1200/JCO.22.00219

FIG 3.

FIG 3.

Linear regressions (red), weighted by circulating tumor cells per mL (point size), showing a decrease in measured log10(HLA I/PD-L1) throughout treatment when on ICB therapy in both the (A) OM and (B) UW cohorts, but not (C) TKI therapy (UW only). Vertical dashed line in (A) indicates when the arm assignment is complete. ICB, immune checkpoint blocker; OM, OMNIVORE; PD-L1, programmed cell death-ligand 1; TKI, tyrosine kinase inhibitor; UW, University of Wisconsin.